{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Endocrine Matters","title":"GLP-1 Receptor Agonists and Type 1 Diabetes: What the Evidence Actually Shows Now","html":"","width":"100%","height":180,"duration":896,"description":"For years, the answer was no. GLP-1 receptor agonists were considered too risky for type 1 diabetes, and the caution traced back to trials that are now nearly a decade old. In 2026, the full picture finally arrived. In this solo episode, board-certified endocrinologist Dr. Arti Thanguduwalks through what the newest evidence actually shows, who stands to benefit, who should be cautious, and exactly how to bring this conversation to your own care team.This episode explores🧩 Why type 1 diabetes is not a childhood disease, and why the cardiovascular and kidney risks that drive mortality are largely preventable🧩 Why the 2016 Adjunct trials raised real safety flags, and why those findings do not generalize to how we practice today🧩 What the newer, better-designed research shows, including the Adjust-T1D trial and the latest real-world outcome data🧩 The 2026 analyses linking GLP-1 use in type 1 to fewer cardiovascular events, less kidney disease, and lower hospitalization, without the feared spikes in DKA or low blood sugar🧩 Who the right candidate is under the ADA 2026 Standards of Care, and who this is not appropriate for🧩 Why this requires an endocrinologist, continuous glucose monitoring, and shared decision-making, never a five-minute prescriptionThis episode is for you ifYou live with type 1 diabetes, love someone who does, or care for these patients, and you want a straight, evidence-based answer about GLP-1 medications instead of either blanket fear or wellness-influencer hype.The bottom lineThe evidence for GLP-1 receptor agonists in type 1 diabetes has crossed a meaningful threshold. These medications remain off-label in type 1 and require endocrinology expertise and close monitoring. But the blanket no is no longer supported by the data, and for the right person, the conversation is worth having now.About the hostDr. Arti Thangudu is a board-certified endocrinologist, founder of Complete Medicine and Hey Healthy, and host of Endocrine Matters. She focuses on...","thumbnail_url":"https://img.transistorcdn.com/LA3-Z5npWAfURN2OcbeyEztCIcEpLMnD4wEPWOmRhWE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wNjJl/MDMyMzEzMTRiNDAz/NzI3NDYwYjIyNWQ3/N2M5MC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}